Chandra Bhagat Pharma Ltd vs Cipla Ltd

A side-by-side comparison of Chandra Bhagat Pharma Ltd (542934) and Cipla Ltd (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Cipla Ltd leads 542934 vs CIPLA on 11 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

8.20
P/E ratio
30.68
0.75
P/B ratio
3.42
0.00%
Dividend yield
0.89%
₹1.14
EPS
₹48.02

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

9.67%
Return on equity
11.60%
6.00%
Return on capital
15.00%
-2.00%
EBITDA margin
21.00%
1.15%
Net margin
13.71%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-1.05%
Revenue CAGR (3Y)
7.37%
43.42%
Profit CAGR (3Y)
10.88%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹25 Cr
Market cap
₹1.19L Cr
₹87 Cr
Revenue
₹28,163 Cr
₹1 Cr
Net profit
₹3,862 Cr
0.50
Debt / equity
0.00
Chandra Bhagat Pharma Ltd
  • + ["Company has reduced debt.", "Stock is trading at 0.73 times its book value", "Promoter holding has increased by 0.83% over last quarter."]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "The company has delivered a poor sales growth of 10.5% over past five years.", "Company has a low return on equity of 5.92% over last 3 years.", "Earnings include an other income of Rs.3.35 Cr.", "Company has high debtors of 171 days."]
Cipla Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.26%"]
Chandra Bhagat Pharma Ltd full analysis Cipla Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.